Skip to search formSkip to main contentSkip to account menu

dabrafenib

Known as: Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro- 
An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (4)

Antineoplastic AgentsImidazolesOximesProtein Kinase Inhibitors
Breast Cancer Resistance Protein Inhibitors [MoA]NCIt Antineoplastic Agent TerminologyOrganic Anion Transporter 1 Inhibitors [MoA]dabrafenib 75 MG Oral Capsule [Tafinlar]

Narrower (3)

GSK 2118436Tafinlardabrafenib mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF…
189Background: Checkpoint inhibitors and targeted therapies have improved outcomes in pts with advanced BRAF V600–mutant melanoma… 
Highly Cited
2016
Highly Cited
2016
Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K…
9502Background: Previous analysis of COMBI-d (NCT01584648) showed that D+T compared with D monotherapy improved ORR (69% [95% CI… 
2016
2016
Profile of vemurafenib‐induced severe skin toxicities
Vemurafenib, a BRAF inhibitor, is commonly associated with skin toxicity. The impact of severe forms is unknown. 
2015
2015
Atg 7 Overcomes Senescence and Promotes Growth of Braf V 600 E-Driven Melanoma
2015
2015
Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
Abstract Background. Small molecules that inhibit V600 mutated BRAF protein, such as vemurafenib and dabrafenib, are effective in… 
Highly Cited
2014
Highly Cited
2014
BRAF inhibitors in cancer therapy.
Highly Cited
2014
Highly Cited
2014
Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic…
2511 Background: D, T, and Ipi are each indicated for treatment of patients (pts) with MM (D+T in BRAF V600 mutation–positive MM… 
Highly Cited
2014
Highly Cited
2014
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
Of 93 patients with pretreated, BRAFV600 mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n… 
Review
2014
Review
2014
New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
The incidence of melanoma has been increasing over the past twenty years. Unfortunately, the prognosis of advanced-stage disease… 
2013
2013
Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib.
IMPORTANCE Approximately 10% to 25% of patients treated with BRAF inhibitors develop cutaneous squamous cell carcinoma (SCC), but… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)